Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
October 11, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
October 11, 2024 06:00 ET
|
Turnstone Biologics Corp.
Turnstone Biologics announces strategic restructuring to prioritize portfolio and extend financial runway.
Upstream Bio Announces Pricing of Upsized Initial Public Offering
October 10, 2024 19:35 ET
|
Upstream Bio
Upstream Bio announces pricing of upsized initial public offering
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
October 10, 2024 01:00 ET
|
Pharming Group N.V.
Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to include ALPS-FAS, CTLA4 haploinsufficiency, NFKB1...
Keck Graduate Institute Ranked the #3 Master’s Program in the Nation for 2025
October 09, 2024 19:31 ET
|
Keck Graduate Institute
Claremont, CA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Keck Graduate Institute is one of the best places to get a master’s degree in the United States according to Intelligent.com’s recently released 2025...
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
October 09, 2024 16:15 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
October 09, 2024 07:00 ET
|
Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
October 09, 2024 02:00 ET
|
Purespring Therapeutics
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde...
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
October 08, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
October 08, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board